{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Excision&page=28", "query": { "intervention": "Excision", "page": 28 }, "page_size": 10 }, "pagination": { "page": 28, "page_size": 10, "total_count": 3675, "total_pages": 368, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Excision&page=29&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Excision&page=27&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T23:35:25.635Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01494662", "title": "HKI-272 for HER2-Positive Breast Cancer and Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "HKI-272", "type": "DRUG" }, { "name": "Surgical Resection", "type": "PROCEDURE" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Ado-Trastuzumab Emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2012-02", "completion_date": "2024-04-19", "has_results": true, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-10-18T23:35:25.635Z", "location_count": 18, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Baltimore, Maryland + 11 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01494662" }, { "nct_id": "NCT02794883", "title": "Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Glioma", "Recurrent Glioblastoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Surgical Procedure", "type": "PROCEDURE" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2016-11-01", "completion_date": "2020-06-17", "has_results": true, "last_update_posted_date": "2022-04-18", "last_synced_at": "2026-10-18T23:35:25.635Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02794883" }, { "nct_id": "NCT06384573", "title": "DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer's Disease", "Dementia", "Alzheimer's Disease, Familial" ], "interventions": [ { "name": "lecanemab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2024-06-10", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-18T23:35:25.635Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Indianapolis, Indiana • St Louis, Missouri + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06384573" }, { "nct_id": "NCT00466505", "title": "Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "celecoxib", "type": "DRUG" }, { "name": "proteomic profiling", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "mass spectrometry", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "GENETIC", "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2005-05", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2012-12-19", "last_synced_at": "2026-10-18T23:35:25.635Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00466505" }, { "nct_id": "NCT00002754", "title": "Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Melanoma (Skin)", "Metastatic Cancer" ], "interventions": [ { "name": "monoclonal antibody Me1-14 F(ab')2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 6, "start_date": "1993-02", "completion_date": "2001-04", "has_results": false, "last_update_posted_date": "2013-02-20", "last_synced_at": "2026-10-18T23:35:25.635Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002754" }, { "nct_id": "NCT06069778", "title": "Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "BNT321 0.5 mg/kg", "type": "DRUG" }, { "name": "BNT321 DL 2", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "BNT321 RP2D", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2024-03-27", "completion_date": "2024-09-18", "has_results": true, "last_update_posted_date": "2025-10-31", "last_synced_at": "2026-10-18T23:35:25.635Z", "location_count": 2, "location_summary": "Los Angeles, California • Charleston, South Carolina", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06069778" }, { "nct_id": "NCT02450591", "title": "Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Oligometastatic Lung Adenocarcinoma" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "Local Therapies", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2015-05-14", "completion_date": "2017-12-11", "has_results": true, "last_update_posted_date": "2018-05-21", "last_synced_at": "2026-10-18T23:35:25.635Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02450591" }, { "nct_id": "NCT01150760", "title": "Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ileus" ], "interventions": [ { "name": "Alvimopan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7050, "start_date": "2010-04", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2015-08-07", "last_synced_at": "2026-10-18T23:35:25.635Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01150760" }, { "nct_id": "NCT06343376", "title": "Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent High Grade B-Cell Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Transformed Chronic Lymphocytic Leukemia", "Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Follicular Lymphoma", "Refractory High Grade B-Cell Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Transformed Chronic Lymphocytic Leukemia", "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "EGFRt/19-28z/IL-12 CAR T-lymphocytes", "type": "BIOLOGICAL" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2024-11-26", "completion_date": "2025-01-03", "has_results": false, "last_update_posted_date": "2025-08-03", "last_synced_at": "2026-10-18T23:35:25.635Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06343376" }, { "nct_id": "NCT04415489", "title": "SIS Versus Office Hysteroscopy for Uterine Cavity Evaluation Prior to IVF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Infertility" ], "interventions": [ { "name": "Office hysteroscopy", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 100, "start_date": "2019-12-06", "completion_date": "2020-12-01", "has_results": true, "last_update_posted_date": "2021-05-19", "last_synced_at": "2026-10-18T23:35:25.635Z", "location_count": 1, "location_summary": "Raleigh, North Carolina", "locations": [ { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04415489" } ] }